The investment from Mercia Ventures and Haatch will fund team expansion and platform enhancements.
"We wanted to make it easier for companies to manage global talent and ensure they have the right people in the right place at the right time. By putting the emphasis on skills, TalentMapper also helps ensure employees are promoted for their capabilities. I have seen so many talented people overlooked for promotion because they weren't a replica of their boss. The funding will enable us to build our team to cope with growing demand, add new features to enhance the platform and scale for growth by targeting other sectors including financial and professional services."
The funding round was backed by existing investors Mercia Ventures, NorthStar Ventures and North East Finance.
"Newcells has a great product and a strong team, and has the potential to become a leader in its field. The past year has been tough for the pharmaceutical industry as economic uncertainty has affected investment, resulting in fewer drugs under development. Newcells has navigated the changing markets effectively, while also improving efficiency and strengthening its commercial team. It is now well positioned for growth as activity levels recover and more companies make the decision to move away from animal testing."
The Series A financing was led by Par Equity to support international expansion and product development.
"Securing this investment allows us to scale our impact across healthcare and life sciences, with a focus on easing the burden of paediatric clinical trials. While legislation like RACE, SPCs, and the ODA has increased study numbers, specialist paediatric knowledge is still lacking in the industry. This has led to lower recruitment, adherence and trial completion rates compared to adult research. Little Journey is uniquely positioned to fill this expertise gap and tackle these challenges to advance global paediatric medicine. With the backing of Par Equity, Mercia Ventures, Octopus Ventures, and our wider investor network, we’re redefining how paediatric clinical trials are run and putting families at the heart of them."
"The success of any surgery depends not only on what happens inside the operating theatre but also on having a smooth-running operation behind the scenes. At Scalpel AI, we work with leading medical device companies and healthcare organisations to transform their logistical supply chain and reduce costs by millions of dollars. Together, we are making surgery safer for patients while paving the way for personalised surgery, which we believe is the future of healthcare."
